Literature DB >> 2900647

Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation.

.   

Abstract

At a maximum follow up of 8 years (median 5 years 6 months) in a randomised trial of adjuvant tamoxifen versus no treatment as therapy for early breast cancer, a significant advantage persists for patients receiving 20 mg of tamoxifen daily for 2 years. This advantage is independent of menopausal status, stage, grade and ER status. Log hazard rate analysis fails to demonstrate a rebound effect on stopping the drug and suggests that more prolonged treatment might further improve results.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2900647      PMCID： PMC2246455          DOI： 10.1038/bjc.1988.138

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  9 in total

1.  Definition of two distinct mechanisms of action of antiestrogens on human breast cancer cell proliferation using hydroxytriphenylethylenes with high affinity for the estrogen receptor.

Authors:  R L Sutherland; C K Watts; P C Ruenitz
Journal:  Biochem Biophys Res Commun       Date:  1986-10-30       Impact factor: 3.575

2.  British interlaboratory quality assessment of steroid receptor assays.

Authors:  S Cowan; R E Leake
Journal:  Recent Results Cancer Res       Date:  1984

3.  Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase.

Authors:  H Y Lam
Journal:  Biochem Biophys Res Commun       Date:  1984-01-13       Impact factor: 3.575

4.  Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells.

Authors:  R L Sutherland; R E Hall; I W Taylor
Journal:  Cancer Res       Date:  1983-09       Impact factor: 12.701

5.  Triphenylethylenes: a new class of protein kinase C inhibitors.

Authors:  C A O'Brian; R M Liskamp; D H Solomon; I B Weinstein
Journal:  J Natl Cancer Inst       Date:  1986-06       Impact factor: 13.506

6.  Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells.

Authors:  C Knabbe; M E Lippman; L M Wakefield; K C Flanders; A Kasid; R Derynck; R B Dickson
Journal:  Cell       Date:  1987-02-13       Impact factor: 41.582

7.  Immunocytochemical demonstration of estrogen receptors by monoclonal antibodies in human breast cancer: correlation with estrogen receptor assay by dextran-coated charcoal method.

Authors:  E Marchetti; P Querzoli; B Moncharmont; I Parikh; A Bagni; A Marzola; G Fabris; I Nenci
Journal:  Cancer Res       Date:  1987-05-01       Impact factor: 12.701

8.  Effects of the antioestrogen tamoxifen on the cell cycle kinetics of the human breast cancer cell line, MCF-7.

Authors:  A E Lykkesfeldt; J K Larsen; I J Christensen; P Briand
Journal:  Br J Cancer       Date:  1984-06       Impact factor: 7.640

9.  Measurement of oestradiol receptors by five institutions on common tissue samples.

Authors:  R J King; D M Barnes; R A Hawkins; R E Leake; P V Maynard; M M Roberts
Journal:  Br J Cancer       Date:  1978-09       Impact factor: 7.640
  9 in total
  33 in total

1.  Suppression of Estrogenic Activity by Medroxyprogesterone Acetate in Tamoxifen-treated Patients after Surgery for Breast Cancer to Reduce the Risk of Endometrial Cancer Development.

Authors: 
Journal:  Breast Cancer       Date:  1996-03-29       Impact factor: 4.239

2.  Clinical and Histological Prognostic Factors in Axillary Node-Negative BreastCancer: Univariate and Multivariate Analysis with Relation to 5-Year Recurrence.

Authors: 
Journal:  Breast Cancer       Date:  1995-04-30       Impact factor: 4.239

3.  Steroid hormone receptor levels and adjuvant tamoxifen in early breast cancer. Ten year results of the Naples (GUN) Study.

Authors:  S De Placido; C Gallo; A Marinelli; F Perrone; C Pagliarulo; G Petrella; G Delrio; M D'Istria; L Del Mastro; A R Bianco
Journal:  Breast Cancer Res Treat       Date:  1990-09       Impact factor: 4.872

Review 4.  Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: AIs upfront vs. switching.

Authors:  Stefan Paepke; Volker R Jacobs; Ralf Ohlinger; Mathias Warm; Sherko Kümmel; Anke Thomas; Nadia Harbeck; Marion Kiechle-Bahat
Journal:  J Cancer Res Clin Oncol       Date:  2007-09-06       Impact factor: 4.553

Review 5.  Endocrine therapy of metastatic breast cancer.

Authors:  A Manni
Journal:  J Endocrinol Invest       Date:  1989-05       Impact factor: 4.256

Review 6.  Systemic therapy in breast cancer: efficacy and cost utility.

Authors:  J F Corry; P E Lønning
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

Review 7.  Systemic adjuvant therapy for node-negative breast cancer.

Authors:  A D Ginsburg; D J Perrault; K I Pritchard; G P Browman; P B McCulloch; J Skillings
Journal:  CMAJ       Date:  1989-09-01       Impact factor: 8.262

Review 8.  Adjuvant systemic therapy: state of the art, 1989.

Authors:  I C Henderson
Journal:  Breast Cancer Res Treat       Date:  1989-10       Impact factor: 4.872

9.  Pathology of endometrium treated with tamoxifen.

Authors:  S M Ismail
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

Review 10.  Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  M M Buckley; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.